Search Results for ""

This year at ONS Congress, you will have the opportunity to view approximately 750 posters presented by colleagues in oncology nursing. While the number of posters can feel a little overwhelming, you can do a few things to maximize this opportunity.

The PowerPort™ ClearVUE™ Implantable Port was designed with nurses and patients in mind. For nurses, PowerPort™ ClearVUE™ offers efficient access and administration, and BD offers port training and maintenance resources. For patients, PowerPort™ ClearVUE™ offers comfort and convenience in the form of two port sizes.

Since the first bispecific antibody (BsAb), blinatumomab, received U.S. Food and Drug Administration approval in 2014, the drug class has developed exponentially, with the majority of currently approved agents entering clinical practice in the past two years. BsAbs are very effective for treating certain malignancies, including multiple myeloma and leukemia, and most are approved for oncology indications. Here’s what makes BsAbs different than other cancer treatments and the key considerations for oncology nursing clinical practice.

In a clinical trial of 65 patients with metastatic or recurrent Merkel cell carcinoma who had not previously received systemic therapy for advanced disease, treatment with retifanlimab-dlwr (Zynyz™) achieved a 52% overall response rate and 18% complete response rate, leading the U.S. Food and Drug Administration to grant it accelerated approval in March 2023.

ONS Congress® is one of my favorite times of the year. Where else can you network with professionals from across the country and earn up to 25 nursing continuing professional development (NCPD) contact hours at the same time? 

Have you dreamed of disseminating all your hard work at the largest conference dedicated to oncology nursing? Did you think you missed the boat after the initial deadline passed? Great news—you can still submit an abstract to the 49th Annual ONS Congress®! There is another opportunity to submit either a research or industry-supported (non-NCPD) late-breaking abstract waiting just for you. 

In 2023, I was able to attend my first ONS Congress® thanks to receiving a scholarship award from my local chapter. That experience was truly life changing for me and how I see myself as a nurse.  

Kelsey Tainsh has experienced much hardship in her young life, but now she seeks to set a positive example for others. Kelsey was diagnosed with a brain tumor at five years old and survived to live a healthy and happy life. She even became a champion athlete. Unfortunately, Kelsey’s tumor returned when she was 15, and she subsequently suffered a devastating stroke. The right side of her body was paralyzed, and Kelsey herself was paralyzed with anxiety and self-doubt.

ONS Congress® returns this spring with the intent to blaze a trail for cutting-edge oncology education and bring together oncology nurses from all over the world. The 2024 ONS Congress Planning Team has been working hard over the past few months to bring extraordinary educational sessions and speakers to Washington, DC, for the 2024 ONS Congress.  

Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer—although it is 40 times rarer than melanoma, it is 3–5 times more lethal. Approximately 3,000 new cases of MCC are diagnosed every year in the United States, but its incidence is increasing because of enhanced diagnostic techniques and the prevalence of risk factors.